Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesGastroenterologyCigna PENFS Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy 0589

    Percutaneous Electrical Nerve Field Stimulation (PENFS)

    Customize your policy alerts

    Sign up for Cigna Policy 0589 alerts

    Get alerted when Policy 0589 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of non-implantable PENFS for abdominal pain associated with irritable bowel syndrome or functional dyspepsia under Cigna-administered health benefit plans, subject to applicable plan documents and coverage criteria.

    Policy Summary
    PayerCigna
    PolicyPercutaneous Electrical Nerve Field Stimulation (PENFS)
    Policy CodePolicy 0589
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateSep 15, 2027
    Key ActionDocument failure of conservative management before an initial PENFS course is considered medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8-21 yearsAge range for medically necessary initial PENFS course
    2Covered abdominal pain-associated disorders
    3Listed contraindications
    2CPT codes listed in the medically necessary coding group
    Insufficient evidenceEvidence for adult use and repeated PENFS courses

    Medical Necessity and Coverage Criteria

    Initial Therapy

    An initial course of PENFS is considered medically necessary when ALL of the following criteria are met:

    Initial PENFS course

    • Covered disorder

      • Irritable bowel syndrome: Persistent abdominal pain associated with irritable bowel syndrome (IBS).
      • Functional dyspepsia: Persistent abdominal pain associated with functional dyspepsia (FD).
    • Conservative management failure: Documented failure of conservative management, such as dietary modification, cognitive behavioral therapy, acid suppression therapy, or antispasmodic medication.
    • Age: The patient is 8 to 21 years old.8 to 21 years
    • Treatment direction: PENFS is delivered as part of a comprehensive treatment plan by or under the direction of a gastroenterologist.
    • No contraindications: The patient does not have hemophilia, a cardiac pacemaker, or psoriasis vulgaris affecting the treatment area.

      All three contraindications must be absent.

    Other Indications

    PENFS is considered not medically necessary for ANY other indication.

    Other indications: PENFS used for any indication other than persistent abdominal pain associated with irritable bowel syndrome or functional dyspepsia is not medically necessary due to insufficient evidence of safety and efficacy.

    Published evidence is presently insufficient to support effectiveness in adults or for repeated courses of PENFS.

    PENFS is not medically necessary when the patient has hemophilia, a cardiac pacemaker, or psoriasis vulgaris affecting the treatment area. All listed contraindications must be absent for an initial course to meet the coverage criteria.

    Published evidence is presently insufficient to support the effectiveness of repeated courses of PENFS.

    PENFS is considered not medically necessary for any indication other than persistent abdominal pain associated with irritable bowel syndrome (IBS) or functional dyspepsia (FD), due to insufficient evidence of safety and efficacy.

    Published evidence is presently insufficient to support the effectiveness of PENFS in the adult population. The available evidence supports an initial course for selected children and adolescents ages 8 to 21 years with refractory IBS or functional dyspepsia.

    Coding and Device Identifiers

    Considered Medically Necessary when criteria in the applicable policy statements listed above are met: CPT CodesCPTCovered
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
    0720TPercutaneous electrical nerve field stimulation, cranial nerves, without implantation (Code deleted 12/31/2025).
    FDA device identifiers and product codemixed
    DEN170018NSS-2 (Bridge) System FDA De Novo identifier
    K173861Drug Relief FDA 510(k) identifier
    PZRFDA product code

    Documentation and Denial Prevention

    Documentation Required

    Document Conservative-Management Failure

    Before requesting an initial PENFS course, document failure of conservative management. Include the therapies attempted and the relevant response or lack of response.

    • Examples include dietary modification, cognitive behavioral therapy (CBT), and medications such as acid suppression therapy or antispasmodics.
    Documentation Required

    Required Clinical Documentation

    Document persistent abdominal pain associated with either irritable bowel syndrome (IBS) or functional dyspepsia (FD), along with the other initial-course requirements. The record must support delivery of PENFS within a comprehensive treatment plan by or under the direction of a gastroenterologist.

    • Persistent abdominal pain must be linked to IBS or FD.
    • Document the patient’s age as 8 to 21 years.
    • Identify the gastroenterologist directing or participating in the comprehensive treatment plan.
    Denial Risk

    Initial-Course Criteria Not Met

    An initial PENFS course is at risk for denial when any initial-course requirement is not met. Confirm the qualifying diagnosis, persistent abdominal pain, age range, conservative-management failure, gastroenterology-directed comprehensive treatment plan, and absence of contraindications before submitting the request.

    • Patient is younger than 8 or older than 21 years.
    • No documented persistent abdominal pain associated with IBS or FD.
    • No documented failure of conservative management.
    • PENFS is not delivered as part of a comprehensive treatment plan by or under the direction of a gastroenterologist.
    • A listed contraindication is present.
    Denial Risk

    Other Indications Not Covered

    PENFS is considered not medically necessary for any indication other than persistent abdominal pain associated with IBS or functional dyspepsia. Requests for a different diagnosis or condition should not be submitted as an initial-course indication under this policy.

    • Coverage is limited to persistent abdominal pain associated with IBS or FD.
    Denial Risk

    Contraindication Present

    Do not proceed with an initial PENFS course when any listed contraindication is present, because the policy requires their absence. Document screening for hemophilia, a cardiac pacemaker, and psoriasis vulgaris affecting the treatment area.

    • Hemophilia.
    • Cardiac pacemaker.
    • Psoriasis vulgaris affecting the treatment area.
    Billing Rule

    Unsupported Coding or Diagnosis

    Use the most appropriate procedure and diagnosis codes in effect on the submission date and ensure they support a covered PENFS indication. Claims billed for unsupported procedure codes, diagnosis codes, conditions, or diagnoses—or submitted without covered codes—may be denied as not covered.

    • Verify that the billed diagnosis is persistent abdominal pain associated with IBS or FD when requesting an initial course.
    • Do not bill PENFS for conditions or diagnoses that are not covered under the policy.
    • Claims lacking applicable covered code(s) are subject to denial as not covered.
    Denial Risk

    Insufficient Evidence for Non-Gastrointestinal Indications

    Evidence is insufficient to support PENFS for postoperative pain or withdrawal symptoms related to substance use disorders. Requests for these indications are at risk for denial as not medically necessary.

    • Published evidence for postoperative pain is limited and mixed.
    • Evidence for withdrawal symptoms related to substance use disorders is limited and insufficient to establish efficacy and safety.

    Background

    Percutaneous electrical nerve field stimulation (PENFS) is a non-implanted electrical stimulation device that delivers nerve stimulation remotely from the source of pain, typically through electrodes placed in and around the ear. For pediatric and adolescent abdominal pain associated with disorders of gut-brain interaction, the device is generally placed in the office, worn for several consecutive days, removed at home, and repeated for up to four consecutive weeks.

    Definitions

    Percutaneous electrical nerve field stimulation (PENFS)
    DefinitionA non-implanted electrical device that provides nerve stimulation primarily for pain relief, remotely from the source of pain.
    Alternate terminologyPercutaneous auricular neurostimulation.
    Typical placementThe device is placed behind the ear, with electrodes in and around the ear to stimulate specific nerves.
    Disorders of gut-brain interaction (DGBI)
    DefinitionA group of disorders characterized by chronic or recurrent gastrointestinal symptoms in the absence of structural disease.
    Underlying symptom mechanismsSymptoms may reflect gastrointestinal motility disturbance, visceral hypersensitivity, altered mucosal or immune function, altered gut microbiota, and/or altered central nervous system processing.
    Abdominal pain-related DGBIAlso termed functional abdominal pain disorders; historically includes functional dyspepsia, irritable bowel syndrome, abdominal migraine, and functional abdominal pain not otherwise specified.
    Functional dyspepsia (FD)
    DefinitionA disorder of gut-brain interaction involving one or more bothersome symptoms occurring at least four times a month for at least two months before diagnosis.
    Qualifying symptomsPostprandial fullness, early satiation, or epigastric pain or burning not associated with defecation.
    Evaluation requirementAfter appropriate evaluation, the symptoms cannot be fully explained by another medical condition.
    Irritable bowel syndrome (IBS)
    DefinitionA disorder of gut-brain interaction involving abdominal pain at least four days per month over at least two months.
    Association criteriaThe pain is associated with defecation, a change in stool frequency, or a change in stool form or appearance.
    Additional requirementsIn children with abdominal pain and constipation, the pain does not resolve when the constipation resolves; after appropriate evaluation, symptoms cannot be fully explained by another medical condition.
    Opioid withdrawal syndrome
    DefinitionThe range of symptoms that occurs after stopping or greatly reducing opioid drugs following heavy and prolonged use.
    Possible symptomsCravings, anxiety, tachycardia, sweating, insomnia, muscle aches, nausea, vomiting, and diarrhea.
    Clinical contextOpioid withdrawal symptoms may occur after opioid dose reduction or cessation.
    Opioid withdrawal management
    DefinitionThe process of withdrawing an individual from a substance safely and effectively under medical supervision.
    First-line treatmentsBuprenorphine and methadone are first-line treatments for opioid withdrawal.
    Possible alternativesAlpha-2 adrenergic agonists may be used as alternatives.
    Multimodal analgesia
    DefinitionUse of two or more agents that employ different mechanisms for pain management.
    Opioid useThe approach avoids excessive use of opioids, while using opioids as needed.
    Examples of interventionsPharmacologic therapies may include acetaminophen, nonsteroidal anti-inflammatory medications, and local or regional analgesia; nonpharmacologic treatments may include compression, elevation, and ice therapy.
    Policy Summary
    PayerCigna
    PolicyPercutaneous Electrical Nerve Field Stimulation (PENFS)
    Policy CodePolicy 0589
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateSep 15, 2027
    Key ActionDocument failure of conservative management before an initial PENFS course is considered medically necessary.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Device IdentifiersDocumentation and Denial PreventionBackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.